康哲藥業(00867.HK)2024年溢利下降32.3%至16.13億元
格隆匯3月17日丨康哲藥業(00867.HK)公吿,截至2024年12月31日止年度業績,營業額下降6.8%至人民幣74.69億元;年度溢利下降32.3%至人民幣16.13億元;每股基本盈利下降31.9%至人民幣0.6673元(2023年:人民幣0.9792元)。建議末期股息每股人民幣0.1174元,使得截至2024年12月31日止年度總股息為每股人民幣0.2681元,較去年下降31.6%(2023年:末期股息和年度總股息分別為每股人民幣0.0783元和人民幣0.3917元)。
2024年,集團新產品研發持續突破,1款新藥獲批上市、1款新增適應症獲批,2款新藥遞交上市申請,新增3款創新藥合作、3款醫美產品合作,超10項臨牀試驗順利推進,以期每年均有創新產品獲批上市。
集團經營業績繼續受第八批國採執行的影響產生同比下降;三個國採產品(黛力新、優思弗、波依定)全按藥品銷售收入合計為人民幣2,691.0百萬元,較2023年同比下降28.8%。除三個進入國採目錄產品外的其他核心產品,絕大多數為獨家產品和創新產品,於報吿期內,非國採獨家產品及創新產品全按藥品銷售收入合計人民幣4,551.3百萬元,較2023年同比增長4.1%,佔營業額的52.8%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.